<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967888</url>
  </required_header>
  <id_info>
    <org_study_id>REP0112</org_study_id>
    <nct_id>NCT01967888</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation</brief_title>
  <official_title>A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dompé Farmaceutici S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dompé Farmaceutici S.p.A</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a phase 2/3, multicenter, double-blind, parallel assignment study. It involves
      100 adult recipients of an intra-hepatic pancreatic Islet Auto-Transplantation (IAT).

      The objective of this clinical trial is to assess whether reparixin leads to improved
      transplant outcome as measured by the proportion of insulin-independent patients following
      IAT. The safety of reparixin in the specific clinical setting will be also evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In contrast to allo-transplantation in type 1 diabetes patients, where immunological
      mechanisms involving allo- and auto-antibodies affect long-term graft function, outcome in
      IAT (Islet Auto-Transplantation) is independent from immunological processes and does not
      require immunosuppression management. On the other hand, early inflammatory events intrinsic
      to the intra-portal islet infusion have been demonstrated to impact islet engraftment. Among
      possible mechanisms, PMNs have been found to be the predominant cell types infiltrating the
      liver in a syngeneic model of islet transplantation in mice.

      Data obtained in experimental models of islet transplantation in mice demonstrate a clear
      effect of reparixin in improving graft survival and function. Protection from the loss and/or
      deterioration of transplanted islets was evident regardless of the immunological mechanisms
      involved in islet damage, suggesting that the ability of reparixin to modulate early
      inflammatory responses readily impact graft outcome.

      Thus, the use of reparixin may emerge as a potential useful medication in the control of non
      specific inflammatory events surrounding the early phases of IAT.

      The goal of this study is to reach a total of 100 adult patients who are randomized and
      receive IAT after total or completion pancreatectomy. Patients will be randomly (1:1)
      assigned to receive either reparixin [continuous i.v. infusion for 7 days (168hrs)], or
      matched placebo (control group),starting approximately 12hrs before islet infusion. The two
      groups will be balanced within each centre. All patients who are randomized and receive the
      Investigational Product (either reparixin or placebo) will be included in the ITT analysis.
      Patients will be in the ITT analysis whether or not they receive IAT, because exclusions
      cannot be made for events occurring after randomization that could be influenced by the
      randomized assignment.

      Recruitment will be competitive among the study sites, until the planned number of patients
      is enrolled. Competitive recruitment has been chosen to increase the speed of recruitment and
      to account for any difference in transplant rate among study sites. Each centre will enroll
      patients as rapidly as possible, up to a maximum of 40 patients (as per the randomization
      list). A maximum of 48 patients is allowed for the site of the Primary Investigator.

      Each patient will be involved in the study for 7 day hospital stay during pancreatectomy
      followed by islet transplantation, for all required measurements up to hospital discharge and
      for 2 post-transplant visits scheduled @ day 75+14 and 365+14 after the transplant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Who Were Insulin Independent After Islet Autotransplantation (IAT) at Day 365±14 Days After Transplant.</measure>
    <time_frame>day 365±14 after the transplant</time_frame>
    <description>Insulin-independence is defined as freedom from the need to take exogenous insulin for 14 or more consecutive days, with adequate glycemic control, as defined by:
a glycated hemoglobin (HbA1c) level &lt;6.5%;
fingerstick fasting blood glucose not exceeding 126 mg/dL more than three times in the past week (based on a minimum of one daily measurement;
a 2 hour post-prandial blood glucose not exceeding 180 mg/dL more than four times in the past week (based on a minimum of one daily measurement);
a laboratory fasting glucose in the non-diabetic range (&lt;126 mg/dL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for the Serum C-peptide Level at Day 75±14 After the Transplant</measure>
    <time_frame>day 75±14 after the transplant</time_frame>
    <description>AUC for the serum C-peptide level is calculated during the first 4 hours of an MMTT, normalized by the number of Islet Equivalent (IEQ)/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for the Serum C-peptide Level at Day 365±14 After the Transplant</measure>
    <time_frame>day 365±14 after the transplant</time_frame>
    <description>AUC for the serum C-peptide level is calculated during the first 4 hours of a mixed meal tolerance test (MMTT), normalized by the number of Islet Equivalent (IEQ)/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daily Insulin Requirements at Day 75±14 After the Transplant</measure>
    <time_frame>day 75±14 after the transplant</time_frame>
    <description>Daily insulin is reported as IU/kg and intake averaged over the previous week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daily Insulin Requirements at Day 365±14 After the Transplant</measure>
    <time_frame>day 365±14 after the transplant</time_frame>
    <description>Daily insulin is reported as IU/kg and intake averaged over the previous week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course From Basal to 240 Min of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant</measure>
    <time_frame>day 75±14 after the transplant</time_frame>
    <description>Data of this outcome are reported as &quot;model estimates over all timepoints&quot;.
This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=43; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=42; 46
30 min; N=40; 46
60 min; N=40; 46
90 min; N=40; 46
120 min; N=41; 46
180 min; N=40; 46
240 min; N=39; 44</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course From Basal to 240 Min of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant</measure>
    <time_frame>day 365±14 after the transplant</time_frame>
    <description>Data are reported as &quot;model estimates over all timepoints&quot;
This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=34; 42 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=34; 41
30 min; N=34; 41
60 min; N=34; 41
90 min; N=34; 41
120 min; N=34; 41
180 min; N=33; 41
240 min; N=33; 41</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course From Basal to 240 Min of C-peptide Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant</measure>
    <time_frame>day 75±14 after the transplant</time_frame>
    <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=44; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=43; 47
30 min; N=41; 47
60 min; N=42; 47
90 min; N=42; 47
120 min; N=42; 47
180 min; N=41; 47
240 min; N=40; 44</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course From Basal to 240 Min of C-peptide Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant</measure>
    <time_frame>day 365±14 after the transplant</time_frame>
    <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=33; 41 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=34; 41
30 min; N=34; 41
60 min; N=33; 41
90 min; N=34; 41
120 min; N=34; 41
180 min; N=33; 40
240 min; N=33; 41</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course From Basal to 240 Min of Insulin Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant</measure>
    <time_frame>day 75±14 after the transplant</time_frame>
    <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=43; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=43; 47
30 min; N=41; 47
60 min; N=41; 47
90 min; N=41; 47
120 min; N=42; 47
180 min; N=41; 47
240 min; N=40; 44</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course From Basal to 240 Min of Insulin Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant</measure>
    <time_frame>day 365±14 after the transplant</time_frame>
    <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=34; 41 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal)
15 min; N=34; 41
30 min; N=34; 41
60 min; N=34; 41
90 min; N=34; 41
120 min; N=34; 41
180 min; N=33; 41
240 min; N=33; 40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>β-cell Function at Day 75±14 After the Transplant</measure>
    <time_frame>day 75±14 after the transplant</time_frame>
    <description>This variable is assessed by β-score (assessment of β-cell function after islet transplantation). The total score is calculated on a 0-8 scoring system (higher is a better outcome) that gives 0-2 points each for:
fasting plasma glucose,
HbA1c,
stimulated C-peptide
insulin requirement subscales. The higher the total score, the better the outcome.
Fasting (or before breakfast) plasma glucose (mg/dL) : ≤99, Score 2; 100-124, Score 1; ≥ 125, Score 0 (the higher the subscore the better the outcome)
HbA1c (%): ≤6.1, Score 2; 6.2-6.9, Score 1; ≥ 7.0, Score 0 (the higher the subscore the better the outcome)
Daily average (previous week) insulin (IU/kg/day): ---, Score 2; 0.01-0.24, Score 1; ≥ 0.25, Score 0 (the higher the subscore the better the outcome)
Stimulated C-peptide (ng/mL): ≥ 0.9, Score 2; 0.3-0.89, Score 1; ≤0.3, Score 0 (the higher the subscore the better the outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>β-cell Function at Day 365±14 After the Transplant</measure>
    <time_frame>day 365±14 after the transplant</time_frame>
    <description>This variable is assessed by β-score (assessment of β-cell function after islet transplantation). The total score is calculated on a 0-8 scoring system (higher is a better outcome) that gives 0-2 points each for glucose, HbA1c, stimulated C-peptide and insulin requirement subscales.
The higher the total score the better the outcome.
Fasting (or before breakfast) plasma glucose (mg/dL) : ≤99, Score 2; 100-124, Score 1; ≥ 125, Score 0 (the higher the subscore the better the outcome)
HbA1c (%): ≤6.1, Score 2; 6.2-6.9, Score 1; ≥ 7.0, Score 0 (the higher the subscore the better the outcome)
Daily average (previous week) insulin (IU/kg/day): ---, Score 2; 0.01-0.24, Score 1; ≥ 0.25, Score 0 (the higher the subscore the better the outcome)
Stimulated C-peptide (ng/mL): ≥ 0.9, Score 2; 0.3-0.89, Score 1; ≤0.3, Score 0 (the higher the subscore the better the outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With an HbA1c &lt;6.5% at Day 365±14 After the Transplant</measure>
    <time_frame>day 365±14 after the transplant</time_frame>
    <description>Percentage of patients with a glycated haemoglobin (HbA1c) &lt;6.5% at day 365±14 after the transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Number of Severe Hypoglycemic Events From Day 75±14 to Day 365±14 After the Transplant</measure>
    <time_frame>from day 75±14 to day 365±14 after the transplant</time_frame>
    <description>A severe hypoglycemic event is defined as an event with one of the following symptoms: &quot;memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms&quot;, in which the subject was unable to treat him/herself and which was associated with either a blood glucose level &lt;54mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With an HbA1c &lt;6.5% at Day 365±14 After the Transplant AND Free of Severe Hypoglycemic Events From Day 75±14 to Day 365±14 After the Transplant Inclusive</measure>
    <time_frame>from day 75±14 to day 365±14 after the transplant</time_frame>
    <description>Percentage of patients with an HbA1c &lt;6.5% at day 365±14 after the transplant AND free of severe hypoglycemic events from day 75±14 to day 365±14 after the transplant inclusive.A severe hypoglycemic event is defined as an event with one of the following symptoms: &quot;memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms&quot;, in which the subject was unable to treat him/herself and which was associated with either a blood glucose level &lt;54mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Adverse Events and Serious Adverse Events Throughout the Study</measure>
    <time_frame>up to day 365±14 after the transplant</time_frame>
    <description>The percentages of patients with any treatment emergent adverse events (TEAE, serious and non serious) and with serious TEAE by severity are presented.
Patients with multiple events within a particular system organ class or preferred term were counted only under the category of their most severe event within that system organ class or preferred term.
A serious AE was defined as any untoward medical occurrence that at any dose:
Resulted in death
Was life-threatening (ie, the patient was at risk of death at the time of the event)
Required inpatient hospitalization or prolongation of existing hospitalization
Resulted in persistent or significant disability/incapacity
Was a congenital anomaly/birth defect
Was an important medical event that, based upon appropriate medical judgment, may have jeopardized the patient and may have required medical or surgical intervention to prevent one of the outcomes listed above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Falling Into One of the Following Malnutrition Risk Levels (Poor Prognosis, Significant Risk, Increased Risk, Normal) According to Pre-albumin Level at Day 75±14 After the Transplant</measure>
    <time_frame>day 75±14 after the transplant</time_frame>
    <description>Malnutrition risk levels are defined as:
Poor prognosis = pre-albumin level &lt;5.0 mg/dL
Significant risk = pre-albumin level 5.0 to 10.9 mg/dL
Increased risk = pre-albumin level 11.0 to 15.0 mg/dL
Normal = pre-albumin level &gt; 15.0 (up to 35.0) mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Falling Into One of the Following Malnutrition Risk Levels (Poor Prognosis, Significant Risk, Increased Risk, Normal) According to Pre-albumin Level at Day 365±14 After the Transplant</measure>
    <time_frame>day 365±14 after the transplant</time_frame>
    <description>Malnutrition risk levels are defined as:
Poor prognosis = pre-albumin level &lt;5.0 mg/dL
Significant risk = pre-albumin level 5.0 to 10.9 mg/dL
Increased risk = pre-albumin level 11.0 to 15.0 mg/dL
Normal = pre-albumin level &gt; 15.0 (up to 35.0) mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients by Steatorrhea Severity at Day 75±14 After the Transplant</measure>
    <time_frame>day 75±14 after the transplant</time_frame>
    <description>Levels of steatorrhea severity (evaluated in the 4 weeks prior to day 75±14 and 365±14), are defined as:
No steatorrhea;
Steatorrhea few times per week;
Steatorrhea daily;
Stool incontinence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients by Steatorrhea Severity at Day 365±14 After the Transplant</measure>
    <time_frame>day 365±14 after the transplant</time_frame>
    <description>Levels of steatorrhea severity (evaluated in the 4 weeks prior to day 75±14 and 365±14), are defined as:
No steatorrhea;
Steatorrhea few times per week;
Steatorrhea daily;
Stool incontinence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Number of Episodes of Documented Asymptomatic Hypoglycemia From Day 75±14 to Day 365±14 After the Transplant</measure>
    <time_frame>from day 75±14 to day 365±14 after the transplant</time_frame>
    <description>The following definition applies:
- Asymptomatic hypoglycemia = An event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration &lt;70mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Number of Episodes of Documented Symptomatic Hypoglycemia From Day 75±14 to Day 365±14 After the Transplant</measure>
    <time_frame>from day 75±14 to day 365±14 after the transplant</time_frame>
    <description>The following definition applies:
- Documented symptomatic hypoglycemia = An event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration &lt;70mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Number of Diabetic Ketoacidosis-related Events</measure>
    <time_frame>from day 75±14 to day 365±14 after the transplant</time_frame>
    <description>A diabetic ketoacidosis event is defined as the presence of:
hyperglycemia (blood glucose &gt;200 mg/dL);
pH &lt;7.3 or HCO3 &lt;15;
ketones positive in the serum or urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak C-peptide at Day 75 After the Transplant</measure>
    <time_frame>Day 75±14 after the transplant</time_frame>
    <description>Peak C-peptide (C-P) is a known predictor of Type 1 Diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak C-peptide at Day 365 After the Transplant</measure>
    <time_frame>Day 365±14 after the transplant</time_frame>
    <description>Peak C-peptide (C-P) is a known predictor of Type 1 Diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-peak C-peptide at Day 75 After the Transplant</measure>
    <time_frame>day 75±14 and day 365±14 after the transplant</time_frame>
    <description>The time-to-peak value in minutes was computed as the time of the peak value (HH:MM on a 24-hour clock) minus the end time of the mixed meal (HH:MM on a 24-hour clock) as recorded on the mixed meal tolerance test Case Report Form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-peak C-peptide at Day 365 After the Transplant</measure>
    <time_frame>Day 365±14 after the transplant</time_frame>
    <description>The time to peak value in minutes will be computed as the time of the peak value (HH:MM on a 24-hour clock) minus the end time of the mixed meal (HH:MM on a 24-hour clock) as recorded on the mixed meal tolerance test CRF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Post-transplant Alanine Aminotransferase (ALT)</measure>
    <time_frame>Baseline, Days 2, 3, 7, 75 ±14 after the transplant</time_frame>
    <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This safety parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
baseline; N=50; 52
Day 2 post-transplant; N=49; 51
Day 3 post-transplant; N=47; 50
Day 7 post-transplant; N=47; 50
Day 75 post-transplant; N=44; 47</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Post-transplant Aspartate Aminotransferase (AST)</measure>
    <time_frame>Baseline, Days 2, 3, 7, 75±14 after the transplant</time_frame>
    <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This safety parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
baseline; N=50; 52
Day 2 post-transplant; N=49; 51
Day 3 post-transplant; N=47; 50
Day 7 post-transplant; N=47; 50
Day 75 post-transplant; N=44; 47</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment Emergent Adverse Events Related to Investigational Product</measure>
    <time_frame>Throughout the study From Day -1 to hospital discharge</time_frame>
    <description>Treatment emergent adverse events - possibly, probably and highly probably - related to investigational product are called &quot;Adverse reactions&quot; (ADR).
An adverse reaction is defined as any untoward medical occurrence in a patient or clinical investigation patient, which has a causal relationship with the administered medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Treatment Emergent Adverse Events Related to Investigational Product</measure>
    <time_frame>Throughout the study From Day -1 to hospital discharge for all adverse events, and from then to day 365 post-transplantation only for serious adverse events</time_frame>
    <description>Serious Treatment emergent adverse events - possibly, probably and highly probably - related to investigational product are called serious &quot;Adverse reactions&quot;.
A serious adverse reaction is defined as any untoward medical occurrence with a causal relationship with the administered medicinal product, that at any dose:
Resulted in death
Was life-threatening (ie, the patient was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.)
Required patient hospitalization or prolongation of existing hospitalization
Resulted in persistent or significant disability/incapacity
Was an important medical event that, based upon appropriate medical judgment, may have jeopardized the patient and may have required medical or surgical intervention to prevent one of the outcomes listed above</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Pancreatectomy for Chronic Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Reparixin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for intravenous (IV) infusion with active compound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physiologic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reparixin</intervention_name>
    <description>Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
    <arm_group_label>Reparixin</arm_group_label>
    <other_name>DF1681Y</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Physiologic solution administered at 0.25 mL/kg/hour</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients eligible for an IAT following total (or completion) pancreatectomy.

          -  Ages &gt; 18 years.

          -  Patients willing and able to comply with the protocol procedures for the duration of
             the study, including scheduled follow-up visits and examinations.

          -  Patients who have given written informed consent, prior to any study-related procedure
             not part of normal medical care, with the understanding that consent may be withdrawn
             by the patient at any time without prejudice to their future medical care.

        Exclusion Criteria:

          -  Recipients of a previous IAT (if completion pancreatectomy).

          -  Patients undergoing total pancreatectomy due to either pancreatic cancer or pancreatic
             benign diseases other than chronic pancreatitis, including insulinomas, etc.

          -  Patients with inadequate renal reserve as per calculated creatinine clearance (CLcr) &lt;
             60 mL/min according to the Cockcroft-Gault formula (1976).

          -  Patients with hepatic dysfunction as defined by increased ALT/AST &gt; 3 x upper limit of
             normal (ULN) or increased total bilirubin above the upper limit at local laboratory).
             Patients with Gilbert's syndrome (elevated unconjugated bilirubin levels in the
             absence of any evidence of hepatic or biliary tract disease) are not excluded.

          -  Patients with a preoperative International Normalized Ratio (INR) &gt; 1.5 or any known
             coagulopathy.

          -  Hypersensitivity to:

               1. ibuprofen or to more than one non steroidal anti-inflammatory drug (NSAID).

               2. medications belonging to the class of sulfonamides, such as sulfamethazine,
                  sulfamethoxazole, sulfasalazine, nimesulide or celecoxib.

          -  Concurrent sepsis (as per positive blood culture(s) and/or fever associated with other
             signs of systemic sepsis syndrome).

          -  Treatment with systemic steroids in the 2 weeks prior to enrolment (except for the use
             of &lt;5mg prednisone daily or equivalent dose of hydrocortisone, for physiological
             replacement only) or with any immune modulators in the 4 weeks prior to enrolment.

          -  Patients with pre-existing diabetes or evidence of impaired β-cells function, based on
             pre-operative fasting blood glucose &gt;115 mg/dL and/or a HbA1c &gt; 6.5%, or requiring
             treatment with any anti-diabetic medication (e.g. insulin, metformin, etc) within the
             2 weeks prior to enrolment.

          -  Use of any investigational agent in the 4 weeks prior to enrolment, including any
             anti-cytokine/chemokine agents.

          -  Pregnant or breast-feeding women; unwillingness to use effective contraceptive
             measures (females and males). (NB: pregnancy should be avoided in patients or partners
             during the first month after completing the treatment with the Investigational
             Product; no other specific warnings are described, considering the treatment course of
             the Investigational Product, its PK profile, and the lack of significant adverse
             effects on mating performance and fertility in animal studies).

          -  Patients with past or current history of alcohol abuse based on clinical history
             and/or past treatment for alcohol addiction.

          -  Patients with evidence of pre-operative portal hypertension as per clinical history
             and abdominal/liver imaging by ultrasound techniques.

        Sites will comply with any additional or more restrictive exclusion criteria locally
        accepted, as per centre practice.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melena Bellin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schulze Diabetes Institute; University of Minnesota Amplatz Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California. Department of Surgery, Division of Transplantation</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schulze Diabetes Institute University of Minnesota Medical School</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas E. Starzl Transplantation Institute University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta, Clinical Islet Transplant Program</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2013</study_first_posted>
  <results_first_submitted>September 15, 2019</results_first_submitted>
  <results_first_submitted_qc>September 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2019</results_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic islet auto-transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT01967888/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 9, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT01967888/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Reparixin</title>
          <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Have Transplant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Research visit not done, data recorded</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject excluded after randomization</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient didn't proceed to pancreatectomy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Unable To Comply With Final Day</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two patients initially randomised to Reparixin received no treatment, hence were not included in the in the population analysed for demographics</population>
      <group_list>
        <group group_id="B1">
          <title>Reparixin</title>
          <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.0" spread="14.4"/>
                    <measurement group_id="B2" value="39.0" spread="10.0"/>
                    <measurement group_id="B3" value="39.5" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Who Were Insulin Independent After Islet Autotransplantation (IAT) at Day 365±14 Days After Transplant.</title>
        <description>Insulin-independence is defined as freedom from the need to take exogenous insulin for 14 or more consecutive days, with adequate glycemic control, as defined by:
a glycated hemoglobin (HbA1c) level &lt;6.5%;
fingerstick fasting blood glucose not exceeding 126 mg/dL more than three times in the past week (based on a minimum of one daily measurement;
a 2 hour post-prandial blood glucose not exceeding 180 mg/dL more than four times in the past week (based on a minimum of one daily measurement);
a laboratory fasting glucose in the non-diabetic range (&lt;126 mg/dL).</description>
        <time_frame>day 365±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Were Insulin Independent After Islet Autotransplantation (IAT) at Day 365±14 Days After Transplant.</title>
          <description>Insulin-independence is defined as freedom from the need to take exogenous insulin for 14 or more consecutive days, with adequate glycemic control, as defined by:
a glycated hemoglobin (HbA1c) level &lt;6.5%;
fingerstick fasting blood glucose not exceeding 126 mg/dL more than three times in the past week (based on a minimum of one daily measurement;
a 2 hour post-prandial blood glucose not exceeding 180 mg/dL more than four times in the past week (based on a minimum of one daily measurement);
a laboratory fasting glucose in the non-diabetic range (&lt;126 mg/dL).</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.542</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>t-test</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.3</ci_lower_limit>
            <ci_upper_limit>000</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for the Serum C-peptide Level at Day 75±14 After the Transplant</title>
        <description>AUC for the serum C-peptide level is calculated during the first 4 hours of an MMTT, normalized by the number of Islet Equivalent (IEQ)/kg</description>
        <time_frame>day 75±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for the Serum C-peptide Level at Day 75±14 After the Transplant</title>
          <description>AUC for the serum C-peptide level is calculated during the first 4 hours of an MMTT, normalized by the number of Islet Equivalent (IEQ)/kg</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
          <units>(ng/mL)/(IEQ/kg)*1000</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5314796" spread="0.3520819"/>
                    <measurement group_id="O2" value="0.6827533" spread="0.4769178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.092</p_value>
            <method>t-test, 2 sided</method>
            <param_type>least square mean difference</param_type>
            <param_value>-0.1601778</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3178030</ci_lower_limit>
            <ci_upper_limit>-0.0025525</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for the Serum C-peptide Level at Day 365±14 After the Transplant</title>
        <description>AUC for the serum C-peptide level is calculated during the first 4 hours of a mixed meal tolerance test (MMTT), normalized by the number of Islet Equivalent (IEQ)/kg</description>
        <time_frame>day 365±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for the Serum C-peptide Level at Day 365±14 After the Transplant</title>
          <description>AUC for the serum C-peptide level is calculated during the first 4 hours of a mixed meal tolerance test (MMTT), normalized by the number of Islet Equivalent (IEQ)/kg</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT</population>
          <units>(ng/mL)/(IEQ/kg)*1000</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5563432" spread="0.3133415"/>
                    <measurement group_id="O2" value="0.6865954" spread="0.4464460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.161</p_value>
            <method>t-test, 2 sided</method>
            <param_type>least square mean difference</param_type>
            <param_value>-0.1178242</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2874310</ci_lower_limit>
            <ci_upper_limit>0.0517825</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Daily Insulin Requirements at Day 75±14 After the Transplant</title>
        <description>Daily insulin is reported as IU/kg and intake averaged over the previous week.</description>
        <time_frame>day 75±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Average Daily Insulin Requirements at Day 75±14 After the Transplant</title>
          <description>Daily insulin is reported as IU/kg and intake averaged over the previous week.</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
          <units>IU/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2125" spread="0.1643"/>
                    <measurement group_id="O2" value="0.2190" spread="0.1589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.846</p_value>
            <method>t-test, 2 sided</method>
            <param_type>least square mean difference</param_type>
            <param_value>0.0136</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0508</ci_lower_limit>
            <ci_upper_limit>0.0781</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Daily Insulin Requirements at Day 365±14 After the Transplant</title>
        <description>Daily insulin is reported as IU/kg and intake averaged over the previous week.</description>
        <time_frame>day 365±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Average Daily Insulin Requirements at Day 365±14 After the Transplant</title>
          <description>Daily insulin is reported as IU/kg and intake averaged over the previous week.</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
          <units>IU/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1723" spread="0.1893"/>
                    <measurement group_id="O2" value="0.1823" spread="0.1994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.817</p_value>
            <method>t-test, 2 sided</method>
            <param_type>least square mean difference</param_type>
            <param_value>-0.025</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0939</ci_lower_limit>
            <ci_upper_limit>0.0689</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course From Basal to 240 Min of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant</title>
        <description>Data of this outcome are reported as &quot;model estimates over all timepoints&quot;.
This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=43; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=42; 46
30 min; N=40; 46
60 min; N=40; 46
90 min; N=40; 46
120 min; N=41; 46
180 min; N=40; 46
240 min; N=39; 44</description>
        <time_frame>day 75±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Time Course From Basal to 240 Min of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant</title>
          <description>Data of this outcome are reported as &quot;model estimates over all timepoints&quot;.
This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=43; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=42; 46
30 min; N=40; 46
60 min; N=40; 46
90 min; N=40; 46
120 min; N=41; 46
180 min; N=40; 46
240 min; N=39; 44</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.0894" spread="11.98160"/>
                    <measurement group_id="O2" value="166.5535" spread="11.45706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.570</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>least square mean difference</param_type>
            <param_value>-9.4641</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.4900</ci_lower_limit>
            <ci_upper_limit>23.5618</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course From Basal to 240 Min of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant</title>
        <description>Data are reported as &quot;model estimates over all timepoints&quot;
This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=34; 42 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=34; 41
30 min; N=34; 41
60 min; N=34; 41
90 min; N=34; 41
120 min; N=34; 41
180 min; N=33; 41
240 min; N=33; 41</description>
        <time_frame>day 365±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Time Course From Basal to 240 Min of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant</title>
          <description>Data are reported as &quot;model estimates over all timepoints&quot;
This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=34; 42 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=34; 41
30 min; N=34; 41
60 min; N=34; 41
90 min; N=34; 41
120 min; N=34; 41
180 min; N=33; 41
240 min; N=33; 41</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.9988" spread="12.00455"/>
                    <measurement group_id="O2" value="180.9442" spread="12.08647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.074</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>least square mean difference</param_type>
            <param_value>-22.9454</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.1826</ci_lower_limit>
            <ci_upper_limit>2.2918</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course From Basal to 240 Min of C-peptide Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant</title>
        <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=44; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=43; 47
30 min; N=41; 47
60 min; N=42; 47
90 min; N=42; 47
120 min; N=42; 47
180 min; N=41; 47
240 min; N=40; 44</description>
        <time_frame>day 75±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Time Course From Basal to 240 Min of C-peptide Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant</title>
          <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=44; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=43; 47
30 min; N=41; 47
60 min; N=42; 47
90 min; N=42; 47
120 min; N=42; 47
180 min; N=41; 47
240 min; N=40; 44</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8976" spread="0.20787"/>
                    <measurement group_id="O2" value="2.1051" spread="0.20104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.358</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>least square mean difference</param_type>
            <param_value>-0.2074</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6538</ci_lower_limit>
            <ci_upper_limit>0.2389</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course From Basal to 240 Min of C-peptide Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant</title>
        <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=33; 41 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=34; 41
30 min; N=34; 41
60 min; N=33; 41
90 min; N=34; 41
120 min; N=34; 41
180 min; N=33; 40
240 min; N=33; 41</description>
        <time_frame>day 365±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Time Course From Basal to 240 Min of C-peptide Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant</title>
          <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=33; 41 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=34; 41
30 min; N=34; 41
60 min; N=33; 41
90 min; N=34; 41
120 min; N=34; 41
180 min; N=33; 40
240 min; N=33; 41</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6052" spread="0.24507"/>
                    <measurement group_id="O2" value="1.8822" spread="0.24763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.288</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>least square mean difference</param_type>
            <param_value>-0.2770</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7936</ci_lower_limit>
            <ci_upper_limit>0.2396</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course From Basal to 240 Min of Insulin Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant</title>
        <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=43; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=43; 47
30 min; N=41; 47
60 min; N=41; 47
90 min; N=41; 47
120 min; N=42; 47
180 min; N=41; 47
240 min; N=40; 44</description>
        <time_frame>day 75±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Time Course From Basal to 240 Min of Insulin Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant</title>
          <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=43; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal).
15 min; N=43; 47
30 min; N=41; 47
60 min; N=41; 47
90 min; N=41; 47
120 min; N=42; 47
180 min; N=41; 47
240 min; N=40; 44</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
          <units>UIU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.67209" spread="3.497499"/>
                    <measurement group_id="O2" value="23.57493" spread="3.378854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.980</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>least square mean difference</param_type>
            <param_value>0.09716</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.41834</ci_lower_limit>
            <ci_upper_limit>7.61266</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course From Basal to 240 Min of Insulin Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant</title>
        <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=34; 41 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal)
15 min; N=34; 41
30 min; N=34; 41
60 min; N=34; 41
90 min; N=34; 41
120 min; N=34; 41
180 min; N=33; 41
240 min; N=33; 40</description>
        <time_frame>day 365±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Time Course From Basal to 240 Min of Insulin Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant</title>
          <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
basal; N=34; 41 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal)
15 min; N=34; 41
30 min; N=34; 41
60 min; N=34; 41
90 min; N=34; 41
120 min; N=34; 41
180 min; N=33; 41
240 min; N=33; 40</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
          <units>UIU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.85522" spread="3.718512"/>
                    <measurement group_id="O2" value="21.77905" spread="3.757573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.785</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>least square mean difference</param_type>
            <param_value>1.07617</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.76562</ci_lower_limit>
            <ci_upper_limit>8.91796</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>β-cell Function at Day 75±14 After the Transplant</title>
        <description>This variable is assessed by β-score (assessment of β-cell function after islet transplantation). The total score is calculated on a 0-8 scoring system (higher is a better outcome) that gives 0-2 points each for:
fasting plasma glucose,
HbA1c,
stimulated C-peptide
insulin requirement subscales. The higher the total score, the better the outcome.
Fasting (or before breakfast) plasma glucose (mg/dL) : ≤99, Score 2; 100-124, Score 1; ≥ 125, Score 0 (the higher the subscore the better the outcome)
HbA1c (%): ≤6.1, Score 2; 6.2-6.9, Score 1; ≥ 7.0, Score 0 (the higher the subscore the better the outcome)
Daily average (previous week) insulin (IU/kg/day): ---, Score 2; 0.01-0.24, Score 1; ≥ 0.25, Score 0 (the higher the subscore the better the outcome)
Stimulated C-peptide (ng/mL): ≥ 0.9, Score 2; 0.3-0.89, Score 1; ≤0.3, Score 0 (the higher the subscore the better the outcome)</description>
        <time_frame>day 75±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>β-cell Function at Day 75±14 After the Transplant</title>
          <description>This variable is assessed by β-score (assessment of β-cell function after islet transplantation). The total score is calculated on a 0-8 scoring system (higher is a better outcome) that gives 0-2 points each for:
fasting plasma glucose,
HbA1c,
stimulated C-peptide
insulin requirement subscales. The higher the total score, the better the outcome.
Fasting (or before breakfast) plasma glucose (mg/dL) : ≤99, Score 2; 100-124, Score 1; ≥ 125, Score 0 (the higher the subscore the better the outcome)
HbA1c (%): ≤6.1, Score 2; 6.2-6.9, Score 1; ≥ 7.0, Score 0 (the higher the subscore the better the outcome)
Daily average (previous week) insulin (IU/kg/day): ---, Score 2; 0.01-0.24, Score 1; ≥ 0.25, Score 0 (the higher the subscore the better the outcome)
Stimulated C-peptide (ng/mL): ≥ 0.9, Score 2; 0.3-0.89, Score 1; ≤0.3, Score 0 (the higher the subscore the better the outcome)</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="1.6"/>
                    <measurement group_id="O2" value="5.2" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.176</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>β-cell Function at Day 365±14 After the Transplant</title>
        <description>This variable is assessed by β-score (assessment of β-cell function after islet transplantation). The total score is calculated on a 0-8 scoring system (higher is a better outcome) that gives 0-2 points each for glucose, HbA1c, stimulated C-peptide and insulin requirement subscales.
The higher the total score the better the outcome.
Fasting (or before breakfast) plasma glucose (mg/dL) : ≤99, Score 2; 100-124, Score 1; ≥ 125, Score 0 (the higher the subscore the better the outcome)
HbA1c (%): ≤6.1, Score 2; 6.2-6.9, Score 1; ≥ 7.0, Score 0 (the higher the subscore the better the outcome)
Daily average (previous week) insulin (IU/kg/day): ---, Score 2; 0.01-0.24, Score 1; ≥ 0.25, Score 0 (the higher the subscore the better the outcome)
Stimulated C-peptide (ng/mL): ≥ 0.9, Score 2; 0.3-0.89, Score 1; ≤0.3, Score 0 (the higher the subscore the better the outcome)</description>
        <time_frame>day 365±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>β-cell Function at Day 365±14 After the Transplant</title>
          <description>This variable is assessed by β-score (assessment of β-cell function after islet transplantation). The total score is calculated on a 0-8 scoring system (higher is a better outcome) that gives 0-2 points each for glucose, HbA1c, stimulated C-peptide and insulin requirement subscales.
The higher the total score the better the outcome.
Fasting (or before breakfast) plasma glucose (mg/dL) : ≤99, Score 2; 100-124, Score 1; ≥ 125, Score 0 (the higher the subscore the better the outcome)
HbA1c (%): ≤6.1, Score 2; 6.2-6.9, Score 1; ≥ 7.0, Score 0 (the higher the subscore the better the outcome)
Daily average (previous week) insulin (IU/kg/day): ---, Score 2; 0.01-0.24, Score 1; ≥ 0.25, Score 0 (the higher the subscore the better the outcome)
Stimulated C-peptide (ng/mL): ≥ 0.9, Score 2; 0.3-0.89, Score 1; ≤0.3, Score 0 (the higher the subscore the better the outcome)</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="2.0"/>
                    <measurement group_id="O2" value="5.4" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.403</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With an HbA1c &lt;6.5% at Day 365±14 After the Transplant</title>
        <description>Percentage of patients with a glycated haemoglobin (HbA1c) &lt;6.5% at day 365±14 after the transplant.</description>
        <time_frame>day 365±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With an HbA1c &lt;6.5% at Day 365±14 After the Transplant</title>
          <description>Percentage of patients with a glycated haemoglobin (HbA1c) &lt;6.5% at day 365±14 after the transplant.</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" lower_limit="49.79" upper_limit="78.78"/>
                    <measurement group_id="O2" value="62.2" lower_limit="48.06" upper_limit="76.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.842</p_value>
            <method>Chi-squared</method>
            <param_type>Treatment effect</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.20</ci_lower_limit>
            <ci_upper_limit>22.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Number of Severe Hypoglycemic Events From Day 75±14 to Day 365±14 After the Transplant</title>
        <description>A severe hypoglycemic event is defined as an event with one of the following symptoms: &quot;memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms&quot;, in which the subject was unable to treat him/herself and which was associated with either a blood glucose level &lt;54mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.</description>
        <time_frame>from day 75±14 to day 365±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of Severe Hypoglycemic Events From Day 75±14 to Day 365±14 After the Transplant</title>
          <description>A severe hypoglycemic event is defined as an event with one of the following symptoms: &quot;memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms&quot;, in which the subject was unable to treat him/herself and which was associated with either a blood glucose level &lt;54mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
          <units>number of events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.94"/>
                    <measurement group_id="O2" value="0.0" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.339</p_value>
            <method>Anderson-Gill model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>34.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With an HbA1c &lt;6.5% at Day 365±14 After the Transplant AND Free of Severe Hypoglycemic Events From Day 75±14 to Day 365±14 After the Transplant Inclusive</title>
        <description>Percentage of patients with an HbA1c &lt;6.5% at day 365±14 after the transplant AND free of severe hypoglycemic events from day 75±14 to day 365±14 after the transplant inclusive.A severe hypoglycemic event is defined as an event with one of the following symptoms: &quot;memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms&quot;, in which the subject was unable to treat him/herself and which was associated with either a blood glucose level &lt;54mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.</description>
        <time_frame>from day 75±14 to day 365±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With an HbA1c &lt;6.5% at Day 365±14 After the Transplant AND Free of Severe Hypoglycemic Events From Day 75±14 to Day 365±14 After the Transplant Inclusive</title>
          <description>Percentage of patients with an HbA1c &lt;6.5% at day 365±14 after the transplant AND free of severe hypoglycemic events from day 75±14 to day 365±14 after the transplant inclusive.A severe hypoglycemic event is defined as an event with one of the following symptoms: &quot;memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms&quot;, in which the subject was unable to treat him/herself and which was associated with either a blood glucose level &lt;54mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1" lower_limit="49.05" upper_limit="79.16"/>
                    <measurement group_id="O2" value="59.1" lower_limit="44.56" upper_limit="73.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.640</p_value>
            <method>Chi-squared</method>
            <param_type>Treatment effect</param_type>
            <param_value>5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.91</ci_lower_limit>
            <ci_upper_limit>25.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence and Severity of Adverse Events and Serious Adverse Events Throughout the Study</title>
        <description>The percentages of patients with any treatment emergent adverse events (TEAE, serious and non serious) and with serious TEAE by severity are presented.
Patients with multiple events within a particular system organ class or preferred term were counted only under the category of their most severe event within that system organ class or preferred term.
A serious AE was defined as any untoward medical occurrence that at any dose:
Resulted in death
Was life-threatening (ie, the patient was at risk of death at the time of the event)
Required inpatient hospitalization or prolongation of existing hospitalization
Resulted in persistent or significant disability/incapacity
Was a congenital anomaly/birth defect
Was an important medical event that, based upon appropriate medical judgment, may have jeopardized the patient and may have required medical or surgical intervention to prevent one of the outcomes listed above</description>
        <time_frame>up to day 365±14 after the transplant</time_frame>
        <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of Adverse Events and Serious Adverse Events Throughout the Study</title>
          <description>The percentages of patients with any treatment emergent adverse events (TEAE, serious and non serious) and with serious TEAE by severity are presented.
Patients with multiple events within a particular system organ class or preferred term were counted only under the category of their most severe event within that system organ class or preferred term.
A serious AE was defined as any untoward medical occurrence that at any dose:
Resulted in death
Was life-threatening (ie, the patient was at risk of death at the time of the event)
Required inpatient hospitalization or prolongation of existing hospitalization
Resulted in persistent or significant disability/incapacity
Was a congenital anomaly/birth defect
Was an important medical event that, based upon appropriate medical judgment, may have jeopardized the patient and may have required medical or surgical intervention to prevent one of the outcomes listed above</description>
          <population>ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.
Eligible patients are included in this population whether or not they receive IAT.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE- Mild events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE - Moderate events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE - Severe events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0"/>
                    <measurement group_id="O2" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serious TEAE- Mild events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0"/>
                    <measurement group_id="O2" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serious TEAE- Moderate events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0"/>
                    <measurement group_id="O2" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serious TEAE- Severe events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0"/>
                    <measurement group_id="O2" value="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Falling Into One of the Following Malnutrition Risk Levels (Poor Prognosis, Significant Risk, Increased Risk, Normal) According to Pre-albumin Level at Day 75±14 After the Transplant</title>
        <description>Malnutrition risk levels are defined as:
Poor prognosis = pre-albumin level &lt;5.0 mg/dL
Significant risk = pre-albumin level 5.0 to 10.9 mg/dL
Increased risk = pre-albumin level 11.0 to 15.0 mg/dL
Normal = pre-albumin level &gt; 15.0 (up to 35.0) mg/dL</description>
        <time_frame>day 75±14 after the transplant</time_frame>
        <population>Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Falling Into One of the Following Malnutrition Risk Levels (Poor Prognosis, Significant Risk, Increased Risk, Normal) According to Pre-albumin Level at Day 75±14 After the Transplant</title>
          <description>Malnutrition risk levels are defined as:
Poor prognosis = pre-albumin level &lt;5.0 mg/dL
Significant risk = pre-albumin level 5.0 to 10.9 mg/dL
Increased risk = pre-albumin level 11.0 to 15.0 mg/dL
Normal = pre-albumin level &gt; 15.0 (up to 35.0) mg/dL</description>
          <population>Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>poor prognosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="8.41"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>significant risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="2.66" upper_limit="22.62"/>
                    <measurement group_id="O2" value="4.3" lower_limit="0.53" upper_limit="14.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>increased risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="29.85" upper_limit="61.33"/>
                    <measurement group_id="O2" value="28.3" lower_limit="15.99" upper_limit="43.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="29.85" upper_limit="61.33"/>
                    <measurement group_id="O2" value="67.4" lower_limit="51.98" upper_limit="80.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Falling Into One of the Following Malnutrition Risk Levels (Poor Prognosis, Significant Risk, Increased Risk, Normal) According to Pre-albumin Level at Day 365±14 After the Transplant</title>
        <description>Malnutrition risk levels are defined as:
Poor prognosis = pre-albumin level &lt;5.0 mg/dL
Significant risk = pre-albumin level 5.0 to 10.9 mg/dL
Increased risk = pre-albumin level 11.0 to 15.0 mg/dL
Normal = pre-albumin level &gt; 15.0 (up to 35.0) mg/dL</description>
        <time_frame>day 365±14 after the transplant</time_frame>
        <population>Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Falling Into One of the Following Malnutrition Risk Levels (Poor Prognosis, Significant Risk, Increased Risk, Normal) According to Pre-albumin Level at Day 365±14 After the Transplant</title>
          <description>Malnutrition risk levels are defined as:
Poor prognosis = pre-albumin level &lt;5.0 mg/dL
Significant risk = pre-albumin level 5.0 to 10.9 mg/dL
Increased risk = pre-albumin level 11.0 to 15.0 mg/dL
Normal = pre-albumin level &gt; 15.0 (up to 35.0) mg/dL</description>
          <population>Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Poor prognosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.61" upper_limit="16.92"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Significant risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.06" upper_limit="13.16"/>
                    <measurement group_id="O2" value="6.8" lower_limit="1.43" upper_limit="18.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" lower_limit="14.60" upper_limit="43.89"/>
                    <measurement group_id="O2" value="9.1" lower_limit="2.53" upper_limit="21.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" lower_limit="48.32" upper_limit="79.37"/>
                    <measurement group_id="O2" value="84.1" lower_limit="69.93" upper_limit="93.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients by Steatorrhea Severity at Day 75±14 After the Transplant</title>
        <description>Levels of steatorrhea severity (evaluated in the 4 weeks prior to day 75±14 and 365±14), are defined as:
No steatorrhea;
Steatorrhea few times per week;
Steatorrhea daily;
Stool incontinence.</description>
        <time_frame>day 75±14 after the transplant</time_frame>
        <population>Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients by Steatorrhea Severity at Day 75±14 After the Transplant</title>
          <description>Levels of steatorrhea severity (evaluated in the 4 weeks prior to day 75±14 and 365±14), are defined as:
No steatorrhea;
Steatorrhea few times per week;
Steatorrhea daily;
Stool incontinence.</description>
          <population>Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>no steatorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="38.85" upper_limit="69.61"/>
                    <measurement group_id="O2" value="64.6" lower_limit="49.46" upper_limit="77.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>steatorrhea few times per week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" lower_limit="16.76" upper_limit="45.20"/>
                    <measurement group_id="O2" value="25.0" lower_limit="13.64" upper_limit="39.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>steatorrhea daily</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="3.79" upper_limit="24.56"/>
                    <measurement group_id="O2" value="6.3" lower_limit="1.31" upper_limit="17.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>stool incontinence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.56" upper_limit="15.47"/>
                    <measurement group_id="O2" value="4.2" lower_limit="0.51" upper_limit="14.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients by Steatorrhea Severity at Day 365±14 After the Transplant</title>
        <description>Levels of steatorrhea severity (evaluated in the 4 weeks prior to day 75±14 and 365±14), are defined as:
No steatorrhea;
Steatorrhea few times per week;
Steatorrhea daily;
Stool incontinence.</description>
        <time_frame>day 365±14 after the transplant</time_frame>
        <population>Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients by Steatorrhea Severity at Day 365±14 After the Transplant</title>
          <description>Levels of steatorrhea severity (evaluated in the 4 weeks prior to day 75±14 and 365±14), are defined as:
No steatorrhea;
Steatorrhea few times per week;
Steatorrhea daily;
Stool incontinence.</description>
          <population>Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>no steatorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="36.42" upper_limit="68.00"/>
                    <measurement group_id="O2" value="58.7" lower_limit="43.23" upper_limit="73.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>steatorrhea few times per week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" lower_limit="13.86" upper_limit="42.04"/>
                    <measurement group_id="O2" value="19.6" lower_limit="9.36" upper_limit="33.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>steatorrhea daily</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="10.30" upper_limit="36.81"/>
                    <measurement group_id="O2" value="21.7" lower_limit="10.95" upper_limit="36.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>stool incontinence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="8.41"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Number of Episodes of Documented Asymptomatic Hypoglycemia From Day 75±14 to Day 365±14 After the Transplant</title>
        <description>The following definition applies:
- Asymptomatic hypoglycemia = An event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration &lt;70mg/dL.</description>
        <time_frame>from day 75±14 to day 365±14 after the transplant</time_frame>
        <population>Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of Episodes of Documented Asymptomatic Hypoglycemia From Day 75±14 to Day 365±14 After the Transplant</title>
          <description>The following definition applies:
- Asymptomatic hypoglycemia = An event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration &lt;70mg/dL.</description>
          <population>Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
          <units>number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="4.3"/>
                    <measurement group_id="O2" value="4.4" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.448</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Number of Episodes of Documented Symptomatic Hypoglycemia From Day 75±14 to Day 365±14 After the Transplant</title>
        <description>The following definition applies:
- Documented symptomatic hypoglycemia = An event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration &lt;70mg/dL.</description>
        <time_frame>from day 75±14 to day 365±14 after the transplant</time_frame>
        <population>Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of Episodes of Documented Symptomatic Hypoglycemia From Day 75±14 to Day 365±14 After the Transplant</title>
          <description>The following definition applies:
- Documented symptomatic hypoglycemia = An event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration &lt;70mg/dL.</description>
          <population>Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
          <units>number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="13.9"/>
                    <measurement group_id="O2" value="4.8" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.910</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Number of Diabetic Ketoacidosis-related Events</title>
        <description>A diabetic ketoacidosis event is defined as the presence of:
hyperglycemia (blood glucose &gt;200 mg/dL);
pH &lt;7.3 or HCO3 &lt;15;
ketones positive in the serum or urine.</description>
        <time_frame>from day 75±14 to day 365±14 after the transplant</time_frame>
        <population>Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of Diabetic Ketoacidosis-related Events</title>
          <description>A diabetic ketoacidosis event is defined as the presence of:
hyperglycemia (blood glucose &gt;200 mg/dL);
pH &lt;7.3 or HCO3 &lt;15;
ketones positive in the serum or urine.</description>
          <population>Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
          <units>number of events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak C-peptide at Day 75 After the Transplant</title>
        <description>Peak C-peptide (C-P) is a known predictor of Type 1 Diabetes.</description>
        <time_frame>Day 75±14 after the transplant</time_frame>
        <population>ITT population: ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Peak C-peptide at Day 75 After the Transplant</title>
          <description>Peak C-peptide (C-P) is a known predictor of Type 1 Diabetes.</description>
          <population>ITT population: ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.640" spread="1.529"/>
                    <measurement group_id="O2" value="2.900" spread="1.753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak C-peptide at Day 365 After the Transplant</title>
        <description>Peak C-peptide (C-P) is a known predictor of Type 1 Diabetes.</description>
        <time_frame>Day 365±14 after the transplant</time_frame>
        <population>ITT Population: ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Peak C-peptide at Day 365 After the Transplant</title>
          <description>Peak C-peptide (C-P) is a known predictor of Type 1 Diabetes.</description>
          <population>ITT Population: ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.630" spread="1.467"/>
                    <measurement group_id="O2" value="3.170" spread="1.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-to-peak C-peptide at Day 75 After the Transplant</title>
        <description>The time-to-peak value in minutes was computed as the time of the peak value (HH:MM on a 24-hour clock) minus the end time of the mixed meal (HH:MM on a 24-hour clock) as recorded on the mixed meal tolerance test Case Report Form.</description>
        <time_frame>day 75±14 and day 365±14 after the transplant</time_frame>
        <population>ITT Population: ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-peak C-peptide at Day 75 After the Transplant</title>
          <description>The time-to-peak value in minutes was computed as the time of the peak value (HH:MM on a 24-hour clock) minus the end time of the mixed meal (HH:MM on a 24-hour clock) as recorded on the mixed meal tolerance test Case Report Form.</description>
          <population>ITT Population: ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.2" spread="93.6"/>
                    <measurement group_id="O2" value="108.7" spread="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-to-peak C-peptide at Day 365 After the Transplant</title>
        <description>The time to peak value in minutes will be computed as the time of the peak value (HH:MM on a 24-hour clock) minus the end time of the mixed meal (HH:MM on a 24-hour clock) as recorded on the mixed meal tolerance test CRF.</description>
        <time_frame>Day 365±14 after the transplant</time_frame>
        <population>ITT Population: ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-peak C-peptide at Day 365 After the Transplant</title>
          <description>The time to peak value in minutes will be computed as the time of the peak value (HH:MM on a 24-hour clock) minus the end time of the mixed meal (HH:MM on a 24-hour clock) as recorded on the mixed meal tolerance test CRF.</description>
          <population>ITT Population: ITT Population consists of all patients who were randomized and received the Investigational Product (either reparixin or placebo). Summarization and analysis of this population is based on randomized treatment, regardless of treatment actually received.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" spread="90.9"/>
                    <measurement group_id="O2" value="102.0" spread="56.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Post-transplant Alanine Aminotransferase (ALT)</title>
        <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This safety parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
baseline; N=50; 52
Day 2 post-transplant; N=49; 51
Day 3 post-transplant; N=47; 50
Day 7 post-transplant; N=47; 50
Day 75 post-transplant; N=44; 47</description>
        <time_frame>Baseline, Days 2, 3, 7, 75 ±14 after the transplant</time_frame>
        <population>Safety Population: Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-transplant Alanine Aminotransferase (ALT)</title>
          <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This safety parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
baseline; N=50; 52
Day 2 post-transplant; N=49; 51
Day 3 post-transplant; N=47; 50
Day 7 post-transplant; N=47; 50
Day 75 post-transplant; N=44; 47</description>
          <population>Safety Population: Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated.</population>
          <units>U/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4105" spread="40.9699"/>
                    <measurement group_id="O2" value="29.0615" spread="40.2724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.5018</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>least square mean difference</param_type>
            <param_value>31.3491</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.9980</ci_lower_limit>
            <ci_upper_limit>123.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Post-transplant Aspartate Aminotransferase (AST)</title>
        <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This safety parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
baseline; N=50; 52
Day 2 post-transplant; N=49; 51
Day 3 post-transplant; N=47; 50
Day 7 post-transplant; N=47; 50
Day 75 post-transplant; N=44; 47</description>
        <time_frame>Baseline, Days 2, 3, 7, 75±14 after the transplant</time_frame>
        <population>Safety population: Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-transplant Aspartate Aminotransferase (AST)</title>
          <description>Data are reported as &quot;model estimates over all timepoints&quot;.
This safety parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively:
baseline; N=50; 52
Day 2 post-transplant; N=49; 51
Day 3 post-transplant; N=47; 50
Day 7 post-transplant; N=47; 50
Day 75 post-transplant; N=44; 47</description>
          <population>Safety population: Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated.</population>
          <units>U/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8755" spread="27.8248"/>
                    <measurement group_id="O2" value="23.3301" spread="26.6545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.4537</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean difference</param_type>
            <param_value>23.5454</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.6619</ci_lower_limit>
            <ci_upper_limit>85.7528</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treatment Emergent Adverse Events Related to Investigational Product</title>
        <description>Treatment emergent adverse events - possibly, probably and highly probably - related to investigational product are called &quot;Adverse reactions&quot; (ADR).
An adverse reaction is defined as any untoward medical occurrence in a patient or clinical investigation patient, which has a causal relationship with the administered medicinal product.</description>
        <time_frame>Throughout the study From Day -1 to hospital discharge</time_frame>
        <population>Safety Population:Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment Emergent Adverse Events Related to Investigational Product</title>
          <description>Treatment emergent adverse events - possibly, probably and highly probably - related to investigational product are called &quot;Adverse reactions&quot; (ADR).
An adverse reaction is defined as any untoward medical occurrence in a patient or clinical investigation patient, which has a causal relationship with the administered medicinal product.</description>
          <population>Safety Population:Safety Population consists of all randomized patients. Summarization and analysis of this population was based on treatment actually received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
          <units>Number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>possibly related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>probably related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>highly probably related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Serious Treatment Emergent Adverse Events Related to Investigational Product</title>
        <description>Serious Treatment emergent adverse events - possibly, probably and highly probably - related to investigational product are called serious &quot;Adverse reactions&quot;.
A serious adverse reaction is defined as any untoward medical occurrence with a causal relationship with the administered medicinal product, that at any dose:
Resulted in death
Was life-threatening (ie, the patient was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.)
Required patient hospitalization or prolongation of existing hospitalization
Resulted in persistent or significant disability/incapacity
Was an important medical event that, based upon appropriate medical judgment, may have jeopardized the patient and may have required medical or surgical intervention to prevent one of the outcomes listed above</description>
        <time_frame>Throughout the study From Day -1 to hospital discharge for all adverse events, and from then to day 365 post-transplantation only for serious adverse events</time_frame>
        <population>Safety population: Safety Population consists of all randomized patients. Summarization and analysis of this population were based on treatment received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
        <group_list>
          <group group_id="O1">
            <title>Reparixin</title>
            <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious Treatment Emergent Adverse Events Related to Investigational Product</title>
          <description>Serious Treatment emergent adverse events - possibly, probably and highly probably - related to investigational product are called serious &quot;Adverse reactions&quot;.
A serious adverse reaction is defined as any untoward medical occurrence with a causal relationship with the administered medicinal product, that at any dose:
Resulted in death
Was life-threatening (ie, the patient was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.)
Required patient hospitalization or prolongation of existing hospitalization
Resulted in persistent or significant disability/incapacity
Was an important medical event that, based upon appropriate medical judgment, may have jeopardized the patient and may have required medical or surgical intervention to prevent one of the outcomes listed above</description>
          <population>Safety population: Safety Population consists of all randomized patients. Summarization and analysis of this population were based on treatment received. Patients randomized but not treated were analyzed in the total summary statistics only.</population>
          <units>Number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>possibly related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>probably related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>highly probably related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day -1 to hospital discharge for all adverse events, and from then to day 365 post-transplantation only for serious adverse events.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Reparixin</title>
          <description>Solution for intravenous (IV) infusion with active compound
Reparixin: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Physiologic solution
Placebo: Physiologic solution administered at 0.25 mL/kg/hour</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E2" events="19" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>small intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Intra-abdominal fluid collection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastrintestinal necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>impaired gastric empting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>intestinal ischeamia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>omental infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastrenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>postoperative abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroparesis postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Post operative hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vascular graft stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypercalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed levele of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Migrane</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Confusion of state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="50"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Haemorragic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Thachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="19" subjects_at_risk="50"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal rigidity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bile acid malabsorption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Jejunal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>mesenteric artery trhombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumatosis intestinalis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Breackthrough pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Generalized oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Secretion discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Penumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Respiratory moniliasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Wound infection fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="50"/>
                <counts group_id="E2" events="43" subjects_affected="43" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Procedural vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urin output decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mean arterial pressure decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood creatinin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood alkalyne phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood zinc decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Catheter culture positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fibrin degradation products increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>International normalized ratio increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Portal vein pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="50"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoinsulinaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypermagnesaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vitamin C deficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Calcium deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypercalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vitamin A deficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Intervertebral disk degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Muscular wickness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ìHeadache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Stupor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyisuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Non reported</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mauro P. Ferrari, Pharm D</name_or_title>
      <organization>Dompé</organization>
      <phone>+3902583831</phone>
      <email>info@dompe.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

